Literature DB >> 10330781

COX 2-selective NSAIDs: biology, promises, and concerns.

B F Mandell1.   

Abstract

Celecoxib (Celebrex) is the first of a new family of nonsteroidal anti-inflammatory drugs (NSAIDs) that selectively inhibit cyclooxygenase 2 (COX 2) while sparing COX 1. Clinical trials indicate that it is approximately as effective in relieving the pain of osteoarthritis and the pain and inflammation of rheumatoid arthritis as nonselective NSAIDs, but causes less gastrointestinal ulceration and bleeding. This paper reviews the pharmacology and possible clinical role of celecoxib and other COX 2-selective NSAIDs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10330781     DOI: 10.3949/ccjm.66.5.285

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN: 0891-1150            Impact factor:   2.321


  5 in total

1.  Interleukin-8, cyclo-oxygenase-2, and trefoil factor family 1 gene expression and their association with Helicobacter pylori infection in the remnant stomach.

Authors:  Chengzhong Xing; Shunji Kato; Norio Matsukura; Noriko Matsuda; Huimian Xu; En Takashi; Nobutaka Yamada; Zenya Naito; Takashi Tajiri
Journal:  Surg Today       Date:  2005       Impact factor: 2.549

2.  Gastrointestinal issues in children with rheumatologic disease.

Authors:  Mirna Chehade; Keith Benkov
Journal:  Curr Rheumatol Rep       Date:  2002-12       Impact factor: 4.592

Review 3.  Cyclooxygenase 2-implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives.

Authors:  F Halter; A S Tarnawski; A Schmassmann; B M Peskar
Journal:  Gut       Date:  2001-09       Impact factor: 23.059

4.  Cross-Reactivity Between Sulfonamides and Loop or Thiazide Diuretics: Is it a Theoretical or Actual Risk?

Authors:  Wanda Phipatanakul; N Franklin Adkinson
Journal:  Allergy Clin Immunol Int       Date:  2000

Review 5.  Erosive osteoarthritis: presentation, clinical pearls, and therapy.

Authors:  G E Ehrlich
Journal:  Curr Rheumatol Rep       Date:  2001-12       Impact factor: 4.686

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.